Related Experiment Video
Updated: Jan 16, 2026
Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
IRS2/FOXO1 mitigates osteoarthritis by regulating chondrocyte autophagy and mitochondrial function
Chaoren Qin1,2, Kai Chen1,2, Yingchun Sun3
1The Yancheng Clinical College of Xuzhou Medical University, Yancheng City, Jiangsu Province, China.
Purpose:
Osteoarthritis (OA) is a debilitating joint disease with no effective cure. This study investigates the role of Insulin Receptor Substrate 2 (IRS2) in OA and its potential as a therapeutic target.
Methods:
Transcriptomic analysis of OA-related datasets (GSE178557, GSE169077, GSE64394, GSE57218) was conducted to identify differentially expressed genes (DEGs), with KEGG pathway analysis highlighting the PI3K/AKT pathway. In vivo, the destabilization of the medial meniscus (DMM) OA mouse model was used to assess IRS2 expression through histology, qPCR, and Western blot. IRS2 was overexpressed in primary mouse chondrocytes via adenoviral transfection, with proliferation, apoptosis, and autophagy assessed by EdU, Annexin V/PI staining, and autophagy-related protein analysis. Adenovirus expressing Irs2 was injected intra-articularly into DMM mice, and cartilage integrity was assessed using histology and micro-CT.
Results:
IRS2 expression was significantly reduced in OA cartilage, correlating with PI3K/AKT pathway inhibition. IRS2 overexpression restored AKT activation, FOXO1 phosphorylation, and mitochondrial autophagy. Intra-articular IRS2 injection improved cartilage matrix integrity, reduced MMP13, and alleviated subchondral bone changes in DMM mice.
Conclusion:
IRS2 plays a key role in OA pathogenesis and targeting it may provide a promising therapeutic approach for OA.
Insights
Insulin Receptor Substrate 2 (IRS2) is reduced in osteoarthritis (OA) cartilage. Restoring IRS2 levels in OA models improved cartilage integrity and reduced disease markers, suggesting IRS2 as a potential therapeutic target for OA.
Area of Science:
- Orthopedics and Rheumatology
- Molecular Biology
- Biomedical Research
Background:
- Osteoarthritis (OA) is a prevalent degenerative joint disease with significant unmet therapeutic needs.
- Current OA treatments primarily manage symptoms, lacking disease-modifying capabilities.
Purpose of the Study:
- To investigate the role of Insulin Receptor Substrate 2 (IRS2) in the pathogenesis of osteoarthritis.
- To evaluate IRS2 as a potential therapeutic target for osteoarthritis treatment.
Main Methods:
- Transcriptomic analysis of OA datasets identified dysregulated genes and pathways, including the PI3K/AKT pathway.
- In vivo studies utilized the destabilization of the medial meniscus (DMM) OA mouse model to assess IRS2 expression and function.
- IRS2 was manipulated in primary chondrocytes and intra-articularly injected into DMM mice to evaluate its effects on OA pathology.
Main Results:
- IRS2 expression was significantly downregulated in OA cartilage, correlating with impaired PI3K/AKT signaling.
- IRS2 overexpression in chondrocytes rescued AKT activation, promoted mitochondrial autophagy, and reduced apoptosis.
- Intra-articular IRS2 delivery in DMM mice ameliorated cartilage degradation, decreased matrix metalloproteinase 13 (MMP13) expression, and improved subchondral bone structure.
Conclusions:
- IRS2 plays a critical role in osteoarthritis pathogenesis by regulating key cellular processes.
- Targeting IRS2 represents a promising novel therapeutic strategy for osteoarthritis.
